Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)	6 Months Ended
	Sep. 30, 2021	Sep. 30, 2020
Cash Flows From Operating Activities:
Net loss	$ (6,837,989)	$ (2,681,273)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	81,691	40,746
Accretion of debt discount	3,502,517	542,428
Mark-To-Market FX revaluation	270,400	0
Stock-based compensation	0	59,000
Changes in assets and liabilities:
Prepaid expenses and other receivables	(94,945)	94,059
Inventory	(264,604)	(125,311)
Accounts payable	(102,302)	(137,999)
Liability due to related parties	(652,349)	(676,560)
Other liabilities and accrued expenses	151,717	(121,357)
Deferred revenue	469,785	0
Net cash used in operating activities	(3,476,079)	(3,006,267)
Cash Flows from Investing Activities:
Capitalized patent costs	(47,426)	(27,600)
Capitalized software development costs	(418,794)	0
Purchase of property and equipment	(220,035)	(14,032)
Net cash used in investing activities	(686,255)	(41,632)
Cash Flows from Financing Activities:
Costs incurred in relation to equity financing	0	(957,193)
Commission paid on note payable	0	(325,000)
Proceeds from issuance of notes	0	5,000,000
Proceeds from issuance of common stock in relation to equity financing	0	15,750,672
Proceeds from warrant exercise	2,963,658	394,475
Repayments of note payable	(3,800,000)	(82,555)
Net cash (used in) provided by financing activities	(836,342)	19,780,399
Net (decrease) increase in cash	(4,998,676)	16,732,500
Effect of exchange rate changes on cash	(98,499)	110,332
Cash at beginning of period	31,865,371	106,107
Cash at end of period	26,768,196	16,948,939
Supplemental disclosure of non-cash financing activities:
Release of prepayment for equity compensation	$ 50,000	$ 0